01321nas a2200337   4500000000100000008004100001260001300042653001500055653001000070653000900080653003000089653001100119653001100130653001200141653000900153653001600162653002900178100001100207700001600218700001100234700001500245700001600260700001200276700001300288245003300301300001000334490000700344050003200351520058600383022001400969       1989                            d  c1989 Apr10aAdolescent10aAdult10aAged10aDrug Therapy, Combination10aFemale10aHumans10aleprosy10aMale10aMiddle Aged10aT-Lymphocytes, Cytotoxic1 aKaur I1 aVaishnavi C1 aKaur S1 aSharma V K1 aGanguly N K1 aKohli M1 aWangoo A00aLymphocytotoxins in leprosy.  a164-80 v61  aInfolep Library - available3 a<p>Lymphocytotoxic antibodies (LCAs) were assayed in serum samples from 60 patients of leprosy spectrum before starting multi-drug therapy (MDT). Seventeen healthy volunteers without any history of viral infection provided control samples. Post treatment follow up samples were also included in the study. In all pretreatment sera of LL, BL and BT/TT patients the levels of LCAs were elevated, the figures were 39.05 +/- 23.87, 44.89 +/- 20.74 and 34.16 +/- 17.50 respectively. With treatment a significant fall in LcAs production was observed in all types of leprosy patients.</p>  a0254-9395